Advanced Analytics. Intelligent Insights.

IXICO helps pharmaceutical and biotech clients to get more from their clinical development programs

logo-outline

Collaboration with Microsoft to support business scale up with global pharma

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces a collaboration with Microsoft to develop its AI data analytics platform for the global pharmaceutical industry.

READ MORE

AD/PD 2021 Poster - Automatic segmentation using deep learning for the hippocampus

READ MORE

Going for growth: IXICO primed to solve the challenge of increased clinical trial complexity through AI advances

Article written by ShareBuyers Editorial Team originally published here As part of the ShareBuyers’ going for growth series, we take a look into the growth prospects of IXICO (IXI), the AIM-listed specialist in AI data analysis for the international clinical trial market which has seen its share price increase by 80% over the past six months....

READ MORE

CHDI - 16th Annual HD Therapeutics Conference

Given the uncertainties resulting from the ongoing COVID-19 pandemic, we have decided to move the 16th Annual HD Therapeutics Conference to a fully online, virtual experience. As in the past we will have scientific presentations, interactive poster sessions, and more – stay tuned for further details in the coming months.

READ MORE

Clinical Trials Project Manager

READ MORE

Consultancy

IXICO has extensive experience in supporting regulatory-compliant clinical research, working with clients on the selection and use of neuroimaging and digital biomarkers - whether directly with your teams or as part of collaborative consortia.

Read more

Early Phase

We have extensive experience in definition and delivery of early phase clinical development, where rigorous patient safety runs hand-in-hand with flexibility around trial design and data analytics.


Read more

Late Phase

IXICO's global network of over 2,000 imaging sites across 75 countries and custom TrialTracker platform ensure that large-scale trials can be set up quickly and efficiently to deliver data that is as reliable as it is regulatory compliant.

Read more

Post-Marketing

IXICO understands the challenges of extended longitudinal studies, and the importance of monitoring patient safety and drug utilization for ongoing optimization of patient pathways post marketing.

Read more

The diseases we work on include:

Alzheimer's Disease (AD)

IXICO is a leadering provider at the forefront of advancing Alzheimer's disease (AD) imaging biomarkers, having focused on AD clinical research since 2007. We have conducted over 40 Alzheimer's disease studies, bringing together deep therapeutic expertise, breakthrough AI analytics and operational agility to deliver extraordinary clinical insights.

Read more

Huntington's Disease (HD)

IXICO is the leading company for Huntington's disease (HD) specialist imaging. Our neuroscience expertise enables global, regulatory compliant imaging and digital biomarker analytical services for clinical development. We are a trusted imaging provider and preferred supplier for pharma and biotech, with IXICO providing advanced imaging analytics for 11 HD trials.

Read more

Parkinson's Disease (PD)

IXICO first supported a clinical study for PD in 2016 and continue to invest in our technological solutions to support clinical trials in this area. PD is the second most common neurodegenerative disease, after Alzheimer’s disease. An estimated 7 to 10 million people worldwide are living with PD.

Read more

Multiple Sclerosis (MS)

We have been involved in MS since 2015 through our Assessa PML collaboration with big pharma. Multiple Sclerosis is a condition that affects the brain and spinal cord. It is the most common autoimmune disorder of the central nervous system, affecting around 2.3 million people globally as of 2015.

Read more

Progressive Supranuclear Palsy

Progressive Supranuclear Palsy (PSP) is a Parkinsonian neurological rare condition caused by the premature loss of nerve cells in certain parts of the brain, which leads to difficulties with balance, movement, vision, speech and swallowing. IXICO has supported clinical trials in this area since 2015, providing advanced analytics for 5 clinical trials across 230 global sites.

Read more

Other Rare Neurological Diseases

IXICO specialises in data collection, optimisation, and analytics of rare neurological disorders, including but not limited to Huntington's Disease (HD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Spinocerebellar Ataxia (SCA).

Read more
Scanner icon 2

Imaging Biomarkers

Scanner icon 2

Imaging Biomarkers

IXICO is at the forefront of the industry in developing and validating unique neuroimaging methods and MRI and PET image analysis techniques, providing more accurate and richer brain structural and functional information.

Digital Brain icon 2

Digital Biomarkers

Digital Brain icon 2

Digital Biomarkers

IXICO is developing and validating new machine learning algorithms to analyse wearable biosensor data for specific neurodegenerative diseases. These disease-specific algorithms can improve the sensitivity and specificity of standard algorithms to measure physiological parameters such as sleep, activity and circadian rhythm.

AI icon 2

Analytics & AI

AI icon 2

Analytics & AI

In neuroscience, AI has applications across the spectrum of understanding and treating the disease. IXICO provides sophisticated AI technology to support clinical development programmes in interpreting complex patient data.

Data platforms icon 2

Data Platforms

Data platforms icon 2

Data Platforms

IXICO's compliant image and digital data management, provides all you need to manage the complex data workflows that come with many clinical trials. IXICO also offers a secure online digital platform as an enabler of clinical decision support for patient selection and post-marketing surveillance.

Subscribe to our mailing list